Please login to the form below

Not currently logged in
Email:
Password:

GSK execs offered consolation payoffs

Two GSK executives may receive significant consolation prizes for not becoming the firm's new CEO, according to UK media reports

Two GlaxoSmithKline (GSK) executives could receive significant consolation prizes for not becoming the firm's new CEO, according to UK media reports.

Chris Viehbacher, who is president of US Pharmaceuticals, and David Stout, who leads pharmaceuticals worldwide, were part of a shortlist of candidates vying for the CEO role which was eventually won by Andrew Whitty.

Both were offered approximately USD 4m in stock and cash and seats on GSK's board to keep them at the company, according to the Sunday Times and the Daily Telegraph who refused to name any sources.

A GSK spokesperson at the company's US headquarters at Research Triangle Park (RTP) in North Carolina made no comment.

Viehbacher is the highest-ranking executive at RTP, while Stout works in Philadelphia. Both were in competition with Whitty to replace Jean-Pierre Garnier, who is set to retire in May 2008.

According to the reports, shareholders have yet to approve the retention packages, which coincide with cost-cutting measures to close sites and slash jobs at RTP and at a manufacturing site nearby. GSK employs about 6,000 people at RTP.

4th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics